Skip to content

AUNERIPHARM

Active Private limited companyfounded 2023active for 2 yearsLouizalaan 480, 1050 BrusselsKBO/BCE: BE 1002.796.292

Lifetime

2 annual accounts with figures on one time axis
peak of €341,530 in 2025
€341,530▲ 55.5%
peak of €92,126 in 2025
€92,126▲ 45.5%
peak of €157,451 in 2025
€157,451▲ 141%
€202,213▲ 12.4%
peak of 1.6 FTE in 2025
1.6 FTE 
Board1 name since 2023
1 director
Documentsfilings and deeds
08-05-202684 days before the deadline
2025financial year
Gross margin from €219,631 to €341,530Result from €63,325 to €92,126Equity from €65,325 to €157,451

Key points

from the 2025 annual accounts

Equity

€157,451 ▲ 141%
€65,3002024€157,0002025

Equity rose in 2025 from €65,325 to €157,451.

Staff

2 employees on 31-12-2025
102024102025

In 2025, 1 employee joined and nobody left.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,329 companies had the same profile as AUNERIPHARM has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,329 companies, not a prediction for AUNERIPHARM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 28-11-2023
  • 2,000 sharesdeed of 01-12-2023
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:1002796292
Incorporation Founding capital of €2,000, 2,000 shares · Founded by · appointed as statutory director · published on 01-12-2023 · Gazette deed
First establishment Louizalaan 480, Brussels
All 6 events

Comparable companies

same main activity, similar in size and age
Company
AUNERIPHARM Brussels €359,664 €341,530 43.8% 1.6
R&G PARTNERS Braine-l'Alleud €497,710 €338,728 34.6% 1.6
Net Circular €191,365 €248,400 55.7% 2.7
Twitter Belgium Saint-Josse-ten-Noode €285,544 €336,083 58.0% 1
VINGT-NEUF Ostend €666,512 €351,492 45.6% 1.8
GHA MANAGEMENT Beauvechain €291,884 €194,231 51.0% 1
STRIVE! Sint-Martens-Latem €369,368 €191,749 45.7% 1.8

These companies have the same main activity as AUNERIPHARM: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €191,000 and €667,000, founded between 2021 and 2025.

Official details

Source: KBO
Status
Active since 29-11-2023Normal situation
Registered office
278 active companies are registered at this addressOf these, 20 started in the 12 months before 19 November 2026. Source: KBO register, as of 19 November 2026.
Activity
Business and other management consultancyNACE 70200
Joint committee
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment unit
2.355.566.9051050 Brussels, since 29-11-2023
Financial year end
31 December
Peppol
Reachable since 03-07-2026
Company details

Annual accounts 2025

≈ €540,000estimated
€359,664▲ 46.7%
Employeeson 31-12-2025
2▲ 100%
Filing
Filed on 08-05-2026, 84 days before the end of the filing period
Financials

Insights on AUNERIPHARM

Solvency rose in 2025 from 26.6% to 43.8% because of the retained profit.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about AUNERIPHARM

What is the company number of AUNERIPHARM?
The company number of AUNERIPHARM is 1002.796.292. The VAT number is the same number with BE in front: BE 1002.796.292.
Where is AUNERIPHARM based?
The registered office is at Louizalaan 480, 1050 Brussels.Company details
What does AUNERIPHARM do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of AUNERIPHARM?
AUNERIPHARM is a private limited company (BV).
When was AUNERIPHARM founded?
AUNERIPHARM was founded on 29-11-2023.
Is AUNERIPHARM still active?
Yes, AUNERIPHARM is an active enterprise in the KBO register.
How many employees does AUNERIPHARM have?
AUNERIPHARM had an average of 1.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does AUNERIPHARM fall under?
In its 2025 annual accounts, AUNERIPHARM states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of AUNERIPHARM?
The turnover in financial year 2025 is about €540,000. This figure is estimated from the gross margin of €341,530 and 73 comparable companies (NACE 70200). It probably lies between €400,000 and €950,000.
Is AUNERIPHARM profitable?
In financial year 2025, AUNERIPHARM made a profit of €92,126.
Where can I find the annual accounts of AUNERIPHARM?
AUNERIPHARM filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of AUNERIPHARM due?
AUNERIPHARM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.